Remarkable progress has been made in the development of new therapies for cancer,
dramatically changing the landscape of treatment approaches for several malignancies and …

Cardiotoxicity is a feared side effect that may limit the clinical use of anthracyclines. It may
indeed affect the quality of life and survival of patients with cancer, regardless of oncological …

Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection
of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position …

Background In patients at risk of cancer therapy-related cardiac dysfunction (CTRCD),
initiation of cardioprotective therapy (CPT) is constrained by the low sensitivity of ejection …

The considerable progress made in the field of cancer treatment has led to a dramatic
improvement in the prognosis of patients with cancer. However, toxicities resulting from …

Abstract Aim Cardiotoxicity (CTox) is a major side effect of cancer therapies, but uniform
diagnostic criteria to guide clinical and research practices are lacking. Methods and results …

Background Left ventricular ejection fraction (LVEF) is an established method for evaluation
of left ventricular (LV) systolic function. Global longitudinal strain (GLS) by speckle tracking …

Echocardiographic imaging is crucial for patient management during cardiotoxic cancer
therapy. Left ventricular ejection fraction is the most commonly used parameter for …

Advances in cancer treatments have improved clinical outcomes, leading to an increasing
population of cancer survivors. However, this success is associated with high rates of short …

Left ventricular (LV) ejection fraction (LVEF) is the most validated and commonly used
echocardiographic measure of systolic function. LVEF has a unique position in cardiology …